Compare OEC & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OEC | ELDN |
|---|---|---|
| Founded | 1862 | 2004 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 300.3M |
| IPO Year | 2014 | 2014 |
| Metric | OEC | ELDN |
|---|---|---|
| Price | $7.66 | $3.83 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $6.56 | ★ $8.50 |
| AVG Volume (30 Days) | 420.7K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,806,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.35 | $1.35 |
| 52 Week High | $12.10 | $4.60 |
| Indicator | OEC | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | 56.35 |
| Support Level | $5.96 | $3.35 |
| Resistance Level | $8.40 | $4.14 |
| Average True Range (ATR) | 0.36 | 0.20 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 84.39 | 59.59 |
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical, and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. The Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing, and special applications. Geographically, it derives a majority of its revenue from Germany.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.